Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/222825
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group |
Autor: | Ocio, Enrique M. CSIC ORCID ; Motlló, Cristina; Rodríguez-Otero, Paula; Martínez-López, Joaquín; Cejalvo, Mª José; Martín-Sánchez, Jesús CSIC ORCID; Bladé, Joan; García‐Malo, Mª Dolores; Dourdil, Mª Victoria; García-Mateo, Aránzazu; Arriba, Felipe de; García-Sanz, Ramón; Rubia, Javier de la; Oriol, Albert; Lahuerta, Juan José; San Miguel, Jesús F. CSIC ORCID; Mateos, Maria Victoria | Fecha de publicación: | 2020 | Editor: | Wiley-VCH | Citación: | British Journal of Haematology: (2020) | Resumen: | This phase I/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty‐seven RRMM patients with a median of three prior lines (2–8) and 94% refractory to lenalidomide were included: 14 in phase I and 33 in phase II. The recommended dose was 1·25 mg/m2 of filanesib on days 1, 2, 15, 16, with pomalidomide 4 mg on days 1–21 and dexamethasone 40 mg weekly. The defined threshold for success was achieved, with 18 out of 31 patients obtaining at least minor response (MR) in the phase II. In the global population, 51% of patients achieved at least partial response (PR) and 60% ≥MR, resulting in a median progression‐free survival (mPFS) of seven months and overall survival (OS) of 19 months. The main toxicity was haematological. Importantly, patients with low serum levels of alpha 1‐acid glycoprotein (AAG) at baseline (<800 mg/l) had a superior response (overall response rate of 62% vs. 17%; P = 0·04), which also translated into a longer mPFS (9 vs. 2 months; P = 0·014). In summary, filanesib with pomalidomide and dexamethasone is active in RRMM although with significant haematological toxicity. Most importantly, high levels of AAG can identify patients unlikely to respond to this strategy. | Versión del editor: | https://doi.org/10.1111/bjh.16788 | URI: | http://hdl.handle.net/10261/222825 | DOI: | 10.1111/bjh.16788 | ISSN: | 0007-1048 | E-ISSN: | 1365-2141 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
8
checked on 12-abr-2024
WEB OF SCIENCETM
Citations
7
checked on 21-feb-2024
Page view(s)
126
checked on 19-abr-2024
Download(s)
54
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.